Ovarian
Featured Articles
(Reuters) Sept 28, 2019 - GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class. The two said separately on Saturday their drug candidates - in a class known as...
Read Article
(Reuters) Sept 26, 2019 - GlaxoSmithKline and AstraZeneca will each present trial data on a promising new class of drugs against ovarian cancer on Saturday as Britain’s top drugmakers compete to burnish their oncology credentials. They will unveil results of studies for rival drugs to block a cancer’s ability to repair its genetic...
Read Article
Latest Articles
October 17, 2019
October 15, 2019
October 15, 2019
October 11, 2019
October 11, 2019
October 10, 2019
October 07, 2019
October 01, 2019
View More
News Commentary
Editor Image
18 Jun, 2019 | by Howard S. Hochster, MD
For patients with germline BRCA mutations, the risk of many cancers and...
View Comment
Editor Image
05 Dec, 2018 | by Debu Tripathy, MD
Very interesting
View Comment
View More
OBR Blog
Several late-breaking studies made a splash today at the 2019 American Society of Clinical Oncology (ASCO) Annual... Read more
June 01, 2019